RT Journal Article
T1 The Effect of Enteral Immunonutrition in the Intensive Care Unit: Does It Impact on Outcomes?
A1 Lopez-Delgado, Juan Carlos
A1 Grau-Carmona, Teodoro
A1 Trujillano-Cabello, Javier
A1 Garcia-Fuentes, Carlos
A1 Mor-Marco, Esther
A1 Bordeje-Laguna, Maria Luisa
A1 Portugal-Rodriguez, Esther
A1 Lorencio-Cardenas, Carol
A1 Vera-Artazcoz, Paula
A1 Macaya-Redin, Laura
A1 Martinez-Carmona, Juan Francisco
A1 Mateu-Campos, Lidon
A1 Gero-Escapa, Maria
A1 Gastaldo-Simeon, Rosa
A1 Vila-Garcia, Belen
A1 Flordelis-Lasierra, Jose Luis
A1 Montejo-Gonzalez, Juan Carlos
A1 Servia-Goixart, Lluis
K1 Enteral nutrition
K1 Immunonutrition
K1 Inflammatory response
K1 Intensive care unit
K1 Outcomes
K1 Protein delivery
AB Background: The present research aimed to evaluate the effect on outcomes of immunonutrition (IMN) enteral formulas during the intensive care unit (ICU) stay. Methods: A multicenter prospective observational study was performed. Patient characteristics, disease severity, nutritional status, type of nutritional therapy and outcomes, and laboratory parameters were collected in a database. Statistical differences were analyzed according to the administration of IMN or other types of enteral formulas. Results: In total, 406 patients were included in the analysis, of whom 15.02% (61) received IMN. Univariate analysis showed that patients treated with IMN formulas received higher mean caloric and protein intake, and better 28-day survival (85.2% vs. 73.3%; p = 0.014. Unadjusted Hazard Ratio (HR): 0.15; 95% CI (Confidence Interval): 0.06−0.36; p< 0.001). Once adjusted for confounding factors, multivariate analysis showed a lower need for vasopressor support (OR: 0.49; 95% CI: 0.26–0.91; p = 0.023) and continuous renal replacement therapies (OR: 0.13; 95% CI: 0.01–0.65; p = 0.049) in those patients who received IMN formulas, independently of the severity of the disease. IMN use was also associated with higher protein intake during the administration of nutritional therapy (OR: 6.23; 95% CI: 2.59–15.54; p < 0.001), regardless of the type of patient. No differences were found in the laboratory parameters, except for a trend toward lower triglyceride levels (HR: 0.97; 95% CI: 0.95–0.99; p = 0.045). Conclusion: The use of IMN formulas may be associated with better outcomes (i.e., lower need for vasopressors and continuous renal replacement), together with a trend toward higher protein enteral delivery during the ICU stay. These findings may ultimately be related to their modulating effect on the inflammatory response in the critically ill.
PB MDPI
YR 2022
FD 2022-05-01
LK http://hdl.handle.net/10668/21475
UL http://hdl.handle.net/10668/21475
LA en
NO Lopez-Delgado JC, Grau-Carmona T, Trujillano-Cabello J, García-Fuentes C, Mor-Marco E, Bordeje-Laguna ML, et al. The Effect of Enteral Immunonutrition in the Intensive Care Unit: Does It Impact on Outcomes? Nutrients. 2022 May 1;14(9):1904
NO The present study was granted by the Spanish Society of Metabolism and Nutrition (SENPE: Sociedad Española de Nutrición y Metabolismo): Best Working Group Project Award at the 34th SENPE National Congress in 2018. We thank CERCA Programme/Generalitat de Catalunya for institutional support.
DS RISalud
RD Apr 6, 2025